Xtratil 250 Tablet contains Cefuroxime 250 mg, a second-generation cephalosporin antibiotic effective against a broad spectrum of Gram-positive and Gram-negative bacteria. It is indicated for the treatment of various bacterial infections including respiratory tract infections such as bronchitis and pneumonia, urinary tract infections, skin and soft tissue infections, otitis media, and Lyme disease. Cefuroxime acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The drug demonstrates stability against beta-lactamase enzymes produced by certain bacteria, enhancing its efficacy against resistant strains. Xtratil 250 is administered orally and is well absorbed from the gastrointestinal tract, achieving therapeutic concentrations in body tissues and fluids. It is generally well tolerated, with common adverse effects including gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypersensitivity reactions may occur, particularly in patients with a history of penicillin allergy. Dose adjustments may be necessary in patients with renal impairment. Xtratil 250 should be used strictly under medical supervision, with therapy duration tailored according to the severity and type of infection. Proper adherence to prescribed dosage is essential to prevent resistance development and ensure optimal clinical outcomes.